

Title: Cost -effectiveness of granulocyte colony stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

Authors: Matti S. Aapro^a, MD, Stephen Chaplin^b, BSc, Paul Cornes^c, BM; Sebastian Howe^d, PhD, Hartmut Link^e, MD, PhD, Natalia Koptelova^d, MD, Andrea Mehl^d, MBA, MPHEco, Mario Di Palma^f, MD, Bridgette Kanz Schroader^g, PharmD, MPA, BCOP, Robert Terkola^{h,i}, PhD, MSc, aHPh.

Affiliations: ^a Genolier Cancer Center, Genolier, Switzerland; ^b Xcenda UK, York; ^c Comparative Outcomes Group, UK; ^d Sandoz International GmbH, Holzkirchen, Germany; ^e Private Practice Hematology Oncology Kaiserslautern, Germany; ^f Gustave Roussy, Paris-Saclay University, Villejuif, France; ^g Xcenda LLC, Carrollton, TX, US; ^h Institute of Science in Healthy Ageing & Healthcare (SHARE, University Medical Center Groningen (UMCG, University of Groningen, The Netherlands); ⁱ Department of Pharmacotherapy and Translational Research, University of Florida -College of Pharmacy, Gainesville, USA

Corresponding author:

Dr Sebastian Howe

Sandoz International GmbH

Industriestr. 18

D-83607 Holzkirchen

Germany

Telephone: +49 8024 4763508


Email address: sebastian.howe@sandoz.com

Online Resource 3: France OWSA


Note: OWSA results for filgrastim in NSCLC are not shown as PP dominated SP.

Abbreviations: FN – febrile neutropenia; G-CSF – granulocyte colony stimulating factor; ICER – incremental cost-effectiveness ratio; kg – kilogram; LOS – length of stay; mcg – microgram; NHL – non-Hodgkin’s lymphoma; NSCLC – non-small cell lung cancer; OWSA – one-way sensitivity analysis; PP – primary prophylaxis; QALY – quality-adjusted life year; RDI – relative dose intensity; SP – secondary prophylaxis.


Breast cancer - filgrastim




NHL - filgrastim



Breast cancer - pegfilgrastim



NSCLC - pegfilgrastim



NHL - pegfilgrastim

